Liminatus Pharma, Inc. filed a Form 8-K on November 18, 2026, disclosing the appointment of Eric Sunghee Kang as Chief Corporate Strategist, effective November 16, 2026.
Key Highlights
- New appointment: Eric Sunghee Kang, age 43, was named Chief Corporate Strategist of Liminatus Pharma, Inc., effective November 16, 2026.
- Reporting line: According to the filing, Mr. Kang will report directly to Chris Kim, the Company's Chief Executive Officer.
- No compensation: The filing states that Mr. Kang will not receive any compensation for his services as Chief Corporate Strategist.
- Current role: Mr. Kang has served as Chief Executive Officer of Quantinum Investment, an investment firm based in Seoul, Korea, since 2022.
- Career background: The filing notes Mr. Kang spent approximately 12 years with global financial institutions, including Morgan Stanley, HSBC, and ING Bank N.V.
- Education: Mr. Kang received a Bachelor of Science in Business from the Leonard N. Stern School of Business at New York University, according to the filing.
Liminatus Pharma Discloses Kang's Role, Background, and Zero-Compensation Arrangement
Liminatus Pharma, Inc. (NASDAQ:LIMN) reported the appointment of Eric Sunghee Kang as Chief Corporate Strategist in a current report filed with the SEC on November 18, 2026, covering an event dated November 16, 2026. According to the filing, Mr. Kang will assist the company with its corporate finance and capital markets strategy, including financing transactions and the development of new business initiatives, in consultation with the Chief Executive Officer.
The filing describes Mr. Kang's professional history in detail. In addition to his current position as Chief Executive Officer of Quantinum Investment since 2022, where he focuses on cross-border capital markets transactions including private investments in public equity and strategic investments in Nasdaq-listed companies, he served as Head of Strategy and Finance of a Nasdaq-listed company in 2025 and as Chief Executive Officer of a Korean asset management firm in 2021. Earlier in his career, the filing states he served as a Research Analyst in the Investment Banking Division of Morgan Stanley in Hong Kong, as a Vice President in the Korean Large Corporates team of the Corporate Banking division of HSBC, and as a Director of Corporate Sales in the Financial Markets division of ING Bank N.V., Seoul Branch.
The filing states that "the Company believes that Mr. Kang's extensive experience in the U.S. and Asian capital markets and in cross-border financing transactions will be valuable to the Company as it pursues additional financing and new business initiatives to enhance stockholder value." The filing also expressly discloses that Mr. Kang will not receive any compensation for his services in this role. The company's common stock and warrants are listed on the Nasdaq Stock Market LLC under the symbols LIMN and LIMNW, respectively.
What Was Disclosed
Liminatus Pharma, Inc. disclosed the appointment of Eric Sunghee Kang, age 43, as Chief Corporate Strategist effective November 16, 2026, including his professional background, reporting structure to CEO Chris Kim, and a zero-compensation arrangement for the role.





Please wait processing your request...